# Aripiprazole and Effexor XR Drug Interaction Study

> **NCT00362271** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 38 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.

## Key facts

- **NCT ID:** NCT00362271
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 38 (—)
- **Last updated:** 2013-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362271, "Aripiprazole and Effexor XR Drug Interaction Study". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00362271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*